Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behcet disease patients

被引:28
作者
Fernandez Bello, Ihosvany [1 ]
Alvarez, Maria T. [1 ]
Lopez-Longo, Francisco J. [2 ]
Arias-Salgado, Elena G. [3 ]
Martin, Monica [1 ]
Jimenez-Yuste, Victor [1 ]
Rodriguez de la Rua, Ana [1 ]
Butta, Nora V. [1 ]
机构
[1] Hosp Univ La Paz IdiPaz, Hematol Unit, Madrid 28046, Spain
[2] Hosp Univ Gregorio Maranon, Rheumatol Unit, Madrid, Spain
[3] Ctr Invest Biol CSIC CIBERER, Dept Cellular & Mol Med, Madrid, Spain
关键词
Behcet disease; CD40L; matrix metalloproteinase 9; platelets; MEG-01; cells; ACUTE CORONARY SYNDROMES; MATRIX-METALLOPROTEINASE EXPRESSION; CARDIOVASCULAR-DISEASE; T-LYMPHOCYTES; LIGAND; CELLS; INVOLVEMENT; ACTIVATION; MECHANISM; RELEASE;
D O I
10.1160/TH11-08-0556
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Platelets are the major source of plasma-soluble CD40L (sCD40L), an important inflammatory mediator. This study explored the impact of platelet-derived sCD40L on Behcet disease (BD), an autoinflammatory vasculitis. We also searched for influences by platelet matrix metalloproteinases (MMP) 2 and MMP-9, implicated in several inflammatory diseases, on CD40L shedding from platelet membrane. Platelet activation were studied by flow cytometry and aggregometry, surface expression of CD40L and platelet-leukocyte aggregates by flow cytometry, sCD40L by ELISA, cellular CD40L and CD40 levels by Western blot and MMPs activity by gelatin zymography. The effect of sCD40L on MMP9 expression was studied in cultured MEG-01 cells. Plasma and platelet-released sCD40L levels were higher in BD patients. No differences in platelet activation and in platelet-leukocyte aggregates formation were observed between BD patients and controls. Plasma and platelet MMP-9 levels were increased in BD patients, whereas there was no difference in platelet MMP-2 activity. Since a correlation between plasma sCD40L and platelet MMP-9 activity was observed, we studied the influence of sCD40L on MMP-9 levels in the megakaryoblastic cell line MEG-01. Treatment of MEG-01 cells with recombinant sCD40L increased MMP-9 but did not change MMP-2 levels. In conclusion, sCD40L release from platelets was mediated by MMP-9, and MMP-9 expression was in turn upregulated by sCD40L in the MEG-01 cell line. We conclude that platelets and megakaryocytes might participate in a positive feedback loop occurring between sCD40L and MMP-9 which would contribute to the proinflammatory state observed in BD.
引用
收藏
页码:88 / 98
页数:11
相关论文
共 56 条
[1]   Circulated activated platelets and increased platelet reactivity in patients with Behcet's disease [J].
Akar, Servet ;
Oezcan, Mehmet Ali ;
Ates, Halil ;
Guerler, Oguz ;
Alacacioglu, Inci ;
Oezsan, G. Hayri ;
Akkoc, Nurullah ;
Oezkan, Sebnem ;
Demirkan, Fatih ;
Onen, Fatos .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2006, 12 (04) :451-457
[2]   Membrane-associated CD40L and sCD40L in atherothrombotic disease [J].
Anand, SX ;
Viles-Gonzalez, JF ;
Badimon, JJ ;
Cavusoglu, E ;
Marmur, JD .
THROMBOSIS AND HAEMOSTASIS, 2003, 90 (03) :377-384
[3]   Platelet-derived CD40L -: The switch-hitting player of cardiovascular disease [J].
André, P ;
Nannizzi-Alaimo, L ;
Prasad, SK ;
Phillips, DR .
CIRCULATION, 2002, 106 (08) :896-899
[4]   CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism [J].
André, P ;
Prasad, KSS ;
Denis, CV ;
He, M ;
Papalia, JM ;
Hynes, RO ;
Phillips, DR ;
Wagner, DD .
NATURE MEDICINE, 2002, 8 (03) :247-252
[5]   Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina -: Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes [J].
Aukrust, P ;
Müller, F ;
Ueland, T ;
Berget, T ;
Aaser, E ;
Brunsvig, A ;
Solum, NO ;
Forfang, K ;
Froland, SS ;
Gullestad, L .
CIRCULATION, 1999, 100 (06) :614-620
[6]   Inflammatory role of platelets in acute coronary syndromes [J].
Aukrust, P ;
Wæhre, T ;
Damås, JK ;
Gullestad, L ;
Solum, NO .
HEART, 2001, 86 (06) :605-606
[7]  
Baharav E, 2006, DRUG DISCOV TODAY, V3, P11, DOI [DOI 10.1016/J.DDMEC.2006.02.005, 10.1016/j.ddmec.2006.02.005]
[8]   Behcet's disease: evaluation of a new instrument to measure clinical activity [J].
Bhakta, BB ;
Brennan, P ;
James, TE ;
Chamberlain, MA ;
Noble, BA ;
Silman, AJ .
RHEUMATOLOGY, 1999, 38 (08) :728-733
[9]   A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis [J].
Boumpas, DT ;
Furie, R ;
Manzi, S ;
Illei, GG ;
Wallace, DJ ;
Balow, JE ;
Vaishnaw, A .
ARTHRITIS AND RHEUMATISM, 2003, 48 (03) :719-727
[10]   Major vessel involvement in Behcet disease [J].
Calamia, KT ;
Schirmer, M ;
Melikoglu, M .
CURRENT OPINION IN RHEUMATOLOGY, 2005, 17 (01) :1-8